Market instability and rising interest rates have reduced investment levels in biotech. And more companies are entering the industry than ever before, increasing competition for funding. These are challenging times, but all is not lost.
According to an investor survey by RBC Capital Markets, 57% of investors believe the biotech sector is undervalued, and 55% predict that biotech will outperform the broader pharma sector.
So, there is no better time than including a whitepaper, as part of your pitch, to demonstrate the potential of your health innovation to prospective investors.
• Highlight your knowledge of the current therapy landscape and unmet medical needs
• Demonstrate the effectiveness and uniqueness of your therapy/device in addressing disease-related challenges
• Write an effective route-to-market and exit strategy